NasdaqGM:RYTMBiotechs
New Setmelanotide Data Shapes Rhythm Pharmaceuticals Obesity Growth Story
Rhythm Pharmaceuticals presented new clinical data on setmelanotide in adults with acquired hypothalamic obesity at the 2026 European Congress of Endocrinology.
The data showed meaningful BMI reductions and improved cardiometabolic outcomes in treated adults.
These findings follow recent pediatric efficacy results shared at the PES Annual Meeting, adding to the evidence base for IMCIVREE across different patient groups.
The updates arrive shortly after regulatory approvals and commercial...